Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06933914
PHASE2/PHASE3

Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria

Sponsor: Wuhan Createrna Science and Technology Co., Ltd

View on ClinicalTrials.gov

Summary

This is a multicenter, single-arm, open-label study to characterize long-term safety and tolerability of MY008211A tablets and to provide access to MY008211A tablets to patients with PNH who have completed Phase 2 or 3 studies with MY008211A tablets.

Official title: An Open Label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of MY008211A Tablets in Patients With PNH Paroxysmal Nocturnal Hemoglobinuria (PNH)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-11-30

Completion Date

2026-12-30

Last Updated

2025-04-18

Healthy Volunteers

No

Interventions

DRUG

MY008211A tablets

Participants will receive MY008211A at a dose of 400 mg orally b.i.d

Locations (1)

Chinese Academy of Medical Sciences Hematology Hospital (Institute of Hematology, Chinese Academy of Medical Sciences)

Tianjin, Tianjin Municipality, China